Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
Go back to Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020| (NASDAQ: ADVM) | Delayed: 4.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.36 | 52 Week High | $4.86 | |||
| Open | $4.36 | 52 Week Low | $2.74 | |||
| Day High | $4.36 | P/E | N/A | |||
| Day Low | $4.36 | EPS | $0.00 | |||
| Volume | 404 | |||||
